Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 11/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.50 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985584 | 0.90 | RXFP1 (0.48) | MTTPNPC1RAB9ARXFP1CASP3 | |
| SCHEMBL4990333 | 0.90 | MTTP (0.51) | MTTPNPC1RAB9ARXFP1CASP3 | |
| SCHEMBL4984087 | 0.88 | MTTP (0.50) | MTTPNR1H4PPARGPPARAPPARD | |
| SCHEMBL4982046 | 0.88 | MTTP (0.56) | MTTPNR1H4PPARGNPC1RAB9A | |
| SCHEMBL5665951 | 0.87 | MTTP (0.45) | MTTPNR1H4PPARGPPARAPPARD | |
| SCHEMBL3175315 | 0.83 | MTTP (0.73) | MTTPNR1H4PPARG | |
| SCHEMBL4987220 | 0.81 | MEN1 (0.58) | MTTPNR1H4PPARGNPC1RAB9A | |
| SCHEMBL5666303 | 0.80 | MTTP (0.56) | MTTP | |
| SCHEMBL4986532 | 0.80 | MTTP (0.49) | MTTP | |
| SCHEMBL3239404 | 0.79 | MTTP (0.83) | MTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468378-B2 | Substituted quinoline compounds | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
| US-20050234099-A1 | Substituted quinoline compounds | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234099-A1 | Substituted quinoline compounds | APOB, APOL1, MTPN | MTTP 9/4885NR1H4 250/4885PPARG 551/4885 |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | MTTP 7/4885NR1H4 111/4885PPARG 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.